0.76
0.76 (0%)
As of Feb 14, 2025
Nextcure, Inc. [NXTC]
Source:
Company Overview
Nextcure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (“ADCs”).
| Country | United States |
| Headquarters | beltsville, maryland |
| Phone Number | 240-399-4900 |
| Industry | manufacturing |
| CEO | Michael Richman |
| Website | www.nextcure.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-59.7 |
| Net Income | $-55.7 |
| Net Cash | $14.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -53.3% |
| Profit as % of Stockholder Equity | -85% |
Management Effectiveness
| Return on Equity | -85% |
| Return on Assets | -68.8% |
| Turnover Ratio | |
| EBITA | $-59.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $80.9 |
| Total Liabilities | $15.4 |
| Operating Cash Flow | $-40.8 |
| Investing Cash Flow | $55.3 |
| Financing Cash Flow | $0.1 |
